In a report released on February 13, Brian Abrahams from RBC Capital maintained a Hold rating on Galapagos (GLPG – Research Report), with a ...

Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Gilead stock surged above a buy zone Wednesday after the company obliterated fourth-quarter forecasts and issued an upbeat ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

As Finance Minister Nirmala Sitharaman will present the Budget 2025 on Saturday at 11 am, experts anticipate that the government will focus on AI-driven initiatives. They suggest that Budget 2025 ...

Today's announcement builds on a collaboration aimed at creating capacity to allow Gilead to continue its focus and mission, aimed at discovering and delivering critical medicines for cancer ...

Focus Features is nearing a deal to produce a feature adaptation of “Audition” based on the 1997 horror-thriller novel by Ryū Murakami, which was originally brought to the screen by Japanese ...

Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as ...